Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

Science Translational Medicine

Volumn 8, Issue 367, 2016, Pages

  Arenas Ramirez, Natalia ^a   Zou, Chao ^b   Popp, Simone ^b   Zingg, Daniel ^c   Brannetti, Barbara ^b   Wirth, Emmanuelle ^b   Calzascia, Thomas ^b   Kovarik, Jiri ^b   Sommer, Lukas ^c   Zenke, Gerhard ^b   Woytschak, Janine ^a   Regnier, Catherine H ^b   Katopodis, Andreas ^b   Boyman, Onur ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; NARA 1; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3; UNCLASSIFIED DRUG; IL2 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MELANOMA; METASTASIS; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BINDING SITE; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; GENE SILENCING; GENETIC RECOMBINATION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; PROTEIN CONFORMATION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; EPITOPES; GENE SILENCING; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PROTEIN CONFORMATION; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 85002343458     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag3187     Document Type: Article

References (35)

1. T. R. Malek, I. Castro, Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33, 153-165 (2010).
2. O. Boyman, J. Sprent, The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180-190 (2012).
3. W. Liao, J.-X. Lin, W. J. Leonard, Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13-25 (2013).
4. N. Arenas-Ramirez, J. Woytschak, O. Boyman, Interleukin-2: Biology, design and application. Trends Immunol. 36, 763-777 (2015).
5. T. Taniguchi, Y. Minami, The IL-2/IL-2 receptor system: A current overview. Cell 73, 5-8 (1993).
6. O. Boyman, M. Kovar, M. P. Rubinstein, C. D. Surh, J. Sprent, Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927 (2006).
7. H. Nishikawa, S. Sakaguchi, Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1-7 (2014).
8. M. W. L. Teng, S. F. Ngiow, B. von Scheidt, N. McLaughlin, T. Sparwasser, M. J. Smyth, Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 70, 7800-7809 (2010).
9. C. Krieg, S. Létourneau, G. Pantaleo, O. Boyman, Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 107, 11906-11911 (2010).
10. R. A. Rosalia, N. Arenas-Ramirez, G. Bouchaud, M. E. Raeber, O. Boyman, Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr. Opin. Chem. Biol. 23, 39-46 (2014).
11. S. Létourneau, E. M. M. van Leeuwen, C. Krieg, C. Martin, G. Pantaleo, J. Sprent, C. D. Surh, O. Boyman, IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl. Acad. Sci. U.S.A. 107, 2171-2176 (2010).
12. X. Wang, M. Rickert, K. C. Garcia, Structure of the quaternary complex of interleukin-2 with its a, β, and gc receptors. Science 310, 1159-1163 (2005).
13. D. J. Stauber, E. W. Debler, P. A. Horton, K. A. Smith, I. A. Wilson, Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 2788-2793 (2006).
14. M. Rickert, X. Wang, M. J. Boulanger, N. Goriatcheva, K. C. Garcia, The structure of interleukin-2 complexed with its alpha receptor. Science 308, 1477-1480 (2005).
15. J. B. Spangler, J. Tomala, V. C. Luca, K. M. Jude, S. Dong, A. M. Ring, P. Votavova, M. Pepper, M. Kovar, K. C. Garcia, Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 42, 815-825 (2015).
16. A. M. Levin, D. L. Bates, A. M. Ring, C. Krieg, J. T. Lin, L. Su, I. Moraga, M. E. Raeber, G. R. Bowman, P. Novick, V. S. Pande, C. G. Fathman, O. Boyman, K. C. Garcia, Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529-533 (2012).
17. G. Rojas, A. Pupo, K. Leon, J. Avellanet, T. Carmenate, S. Sidhu, Deciphering the molecular bases of the biological effects of antibodies against interleukin-2: A versatile platform for fine epitope mapping. Immunobiology 218, 105-113 (2013).
18. D. Marvel, D. I. Gabrilovich, Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J. Clin. Invest. 125, 3356-3364 (2015).
19. E. J. Wherry, S.-J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, R. Ahmed, Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27, 670-684 (2007).
20. K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, A. C. Anderson, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
21. P. Sharma, J. P. Allison, The future of immune checkpoint therapy. Science 348, 56-61 (2015).
22. J. Ackermann, M. Frutschi, K. Kaloulis, T. McKee, A. Trumpp, F. Beermann, Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005-4011 (2005).
23. D. Zingg, J. Debbache, S. M. Schaefer, E. Tuncer, S. C. Frommel, P. Cheng, N. Arenas-Ramirez, J. Haeusel, Y. Zhang, M. Bonalli, M. T. McCabe, C. L. Creasy, M. P. Levesque, O. Boyman, R. Santoro, O. Shakhova, R. Dummer, L. Sommer, The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 6, 6051 (2015).
24. A. Yu, I. Snowhite, F. Vendrame, M. Rosenzwajg, D. Klatzmann, A. Pugliese, T. R. Malek, Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64, 2172-2183 (2015).
25. S. A. Rosenberg, IL-2: The first effective immunotherapy for human cancer. J. Immunol. 192, 5451-5458 (2014).
26. D. J. Schwartzentruber, D. H. Lawson, J. M. Richards, R. M. Conry, D. M. Miller, J. Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, K. L.Kendra,R. L.White, R. Gonzalez,T. M.Kuzel, B. Curti, P. D. Leming, E. D. Whitman, J. Balkissoon, D. S. Reintgen, H. Kaufman, F. M. Marincola, M. J. Merino, S. A. Rosenberg, P. Choyke, D. Vena, P. Hwu, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011).
27. C. Klein, I. Waldhauer, V. Nicolini, C. Dunn, A. Freimoser-Grundschober, S. Herter, E. Geven, O. Boerman, T. Nayak, E. van Puijenbroek, D. Wittig, S. Moser, O. Ast, P. Bruenker, R. Hosse, S. Lang, S. Neumann, H. Kettenberger, A. Grossmann, I. Gorr, S. Evers, P. Pisa, J. Fretland, V. Levitsky, C. Gerdes, M. Bacac, E. Moessner, P. Umaña, Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer. Cancer Res. 73, 486 (2013).
28. D. H. Charych, U. Hoch, J. L. Langowski, S. R. Lee, M. K. Addepalli, P. B. Kirk, D. Sheng, X. Liu, P. W. Sims, L. A. VanderVeen, C. F. Ali, T. K. Chang, M. Konakova, R. L. Pena, R. S. Kanhere, Y. M. Kirksey, C. Ji, Y. Wang, J. Huang, T. D. Sweeney, S. S. Kantak, S. K. Doberstein, NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680-690 (2016).
29. F. D. Finkelman, K. B. Madden, S. C. Morris, J. M. Holmes, N. Boiani, I. M. Katona, C. R. Maliszewski, Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-Anti-cytokine antibody complexes. J. Immunol. 151, 1235-1244 (1993).
30. L. T. May, R. Neta, L. L. Moldawer, J. S. Kenney, K. Patel, P. B. Sehgal, Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J. Immunol. 151, 3225-3236 (1993).
31. O. Boyman, C. Ramsey, D. M. Kim, J. Sprent, C. D. Surh, IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J. Immunol. 180, 7265-7275 (2008).
32. M. P. Rubinstein, M. L. Salem, A. L. Doedens, C. J. Moore, C. Chiuzan, G. L. Rivell, D. J. Cole, A. W. Goldrath, G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J. Hematol. Oncol. 6, 75 (2013).
33. J. Woytschak, N. Keller, C. Krieg, D. Impellizzieri, R. W. Thompson, T. A. Wynn, A. S. Zinkernagel, O. Boyman, Type 2 interleukin-4 receptor signaling in neutrophils antagonizes their expansion and migration during infection and inflammation. Immunity 45, 172-184 (2016).
34. O. Boyman, J.-H. Cho, J. T. Tan, C. D. Surh, J. Sprent, A major histocompatibility complex class I-dependent subset of memory phenotype CD8+ cells. J. Exp. Med. 203, 1817-1825 (2006).
35. M. C. W. Feltkamp, H. L. Smits, M. P. M. Vierboom, R. P. Minnaar, B. M. De Jongh, J. W. Drijfhout, J. Ter Schegget, C. J. M. Melief, W. M. Kast, Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249 (1993).